Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

Ejemplares similares

• The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
  por: Liu, Chien-Ying, et al.
  Publicado: (2017)
• Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
  por: Chang, John Wen‐Cheng, et al.
  Publicado: (2022)
• Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
  por: Ko, How-Wen, et al.
  Publicado: (2022)
• Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
  por: Tu, Chih-Yen, et al.
  Publicado: (2018)
• The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
  por: Wu, Shang-Gin, et al.
  Publicado: (2020)